Biotech Values

[DewDiligence]

The threat to NVO’s franchise from biosimilars is genuine, IMO. Insulin is the simplest of all proteins. Producing knockoffs of any of the currently marketed insulin analogs ought to be a piece of cake compared to the effort MNTA/NVS undertook for Lovenox and Copaxone.